Plasminogen Activator Inhibitor Type 1, 6X His-Tag, Human (PAI-1)
Plasminogen Activator Inhibitor 1 (PAI-1) is a glycoprotein found in plasma that is implicated in the processes of angiogenesis, hemostasis, tumor metastasis, fibrionlysis, ovulation, embryonic development and inflammation (1). The elevation of PAI-1 has shown to correlate with the prognosis of many cancers including breast cancer (2,3,4). PAI-1 is activated by the glycoprotein vitronectin. Vitronectin binds to PAI-1 and modulates fibrinolysis and cell migration (5). This binding has proven to be an important inhibitor of the activated form of protein C (APC) (6).
This Human PAI-1 is a collection of four mutations: K154T, Q139L, M354I and H150H. These mutations offer great stability while locking into the active conformaton. The N-terminus has been additionally modified with the coupling of a 6-X His tag.
Solubility
>2mg/ml and <5mg/ml
Absorbance (280nm)
1.65 E0.1% = 1.0
Second order rate constants for inhibition of
UPA = 6.3 X 106 M^-1s^-1 tPA = 5.7 X 106 M^-1s^-1
Storage and Stability
Aliquot to avoid repeated freezing and thawing and store at -70°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquots are stable for at least 12 months.
Purity
≥99% pure by SDS PAGE 98 ±2% active by uPA titration.
Form
Supplied as a liquid in PBS, pH 5.8
Important Note
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
